EN ISO 13485:2016 – Amendment 11 has been published!
The European standardisation bodies CEN and CENELEC published EN ISO 13485:2016+A11:2021 featuring new annexes ZA and ZB that link the requirements of the MDR (Regulation EU 2017/745) and the IVDR (Regulation EU 2017/746), respectively, to specific clauses of the standard.
Liliana Teles

Liliana Teles

Regulatory Affairs Manager

On the 9th of September, the European standardisation bodies CEN and CENELEC published the 2021 amendment, EN ISO 13485:2016+A11:2021 – ‘Medical devices – Quality management systems – Requirements for regulatory purposes’, featuring new annexes ZA and ZB that link the requirements of the Medical Device Regulation (MDR, EU 2017/745) and the In Vitro Diagnostics Regulation (IVDR, EU 2017/746), respectively, to specific clauses of the standard.

EN ISO 13485:2016+A11:2021 provides regulatory requirements for the manufacturer’s Quality Management System (QMS) that ensures consistent design, development, production, installation, and delivery of medical devices. Although ISO 13485:2016 is not mandatory for EU MDR/IVDR compliance, it is a commonly acknowledged standard to demonstrate the compliance to the MDR/IVDR requirement of having a QMS implemented.

What is new?

The new Annexes link clauses of the standard with requirements in the MDR and IVDR on:

– The general obligations of the manufacturer in MDR/IVDR Article 10 (Tables ZA1 for MDR and ZB1 for IVDR);

– The quality management system (QMS) requirements in MDR/IVDR Annex IX on conformity assessment based on a QMS and on assessment of technical documentation (Table ZA2 for MDR and ZB2 for IVDR); and

– The QMS requirements in MDR/IVDR Annex XI on conformity assessment based on product conformity verification (Table ZA3 for MDR and ZB3 for IVDR).

Annexes ZA and ZB publication now clarifies where compliance with the standard is not sufficient, or only partly sufficient, to meet EU regulatory requirements.

It is expected that the European Commission will add EN ISO 13485:2016+A11:2021 to the slowly growing list of standards harmonized under the MDR and the IVDR before the end of 2021, once reference to this standard is published in the Official Journal of the European Union, which would then allow medical device manufacturers to claim a presumption of conformity with identified clauses of the MDR/IVDR.

The current list of standards harmonized under the MDR/IVDR can be accessed here.

If you wish to know more information about amendment EN ISO 13485:2016+A11:2021 – ‘Medical devices – Quality management systems – Requirements for regulatory purposes’ feel free to contact us at info@criticalcatalyst.com.

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »